Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HUTCHMED (China) ( (HK:0013) ) has provided an announcement.
HUTCHMED said that non-performance-based share awards granted under its Long Term Incentive Plan on March 13, 2024, to Chief Executive Officer and Chief Scientific Officer Dr Weiguo Su vested on March 13, 2026. The vesting covers 19,913 ordinary shares awarded at nil cost and was executed outside a trading venue, reflecting ongoing equity-based remuneration for senior leadership.
The company disclosed the transaction in line with UK Market Abuse Regulation requirements for persons discharging managerial responsibilities. The move underscores HUTCHMED’s use of long-term equity incentives to align executive interests with shareholders as it advances its oncology and immunology portfolio globally.
More about HUTCHMED (China)
HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It develops drug candidates in-house, with three medicines already marketed in China and one also approved in major global markets including the U.S., Europe and Japan.
For an in-depth examination of 0013 stock, go to TipRanks’ Overview page.